Seminars in Hematology
Volume 42, Issue 4 , Pages 181-183 , October 2005

Chronic Myeloproliferative Disorders—Introduction

References 

  1. Dameshek W . Some speculations on the myeloproliferative syndromes . Blood . 1951;6:372
  2. Murphy S . Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia . Semin Hematol . 1999;36:9–13
  3. Pearson TC . Evaluation of diagnostic criteria in polycythemia vera . Semin Hematol . 2001;38:21–24
  4. Vardiman JW , Harris NL , Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms . Blood . 2002;100:2292–2302
  5. Vogelstein B , Fearon ER , Hamilton SR , Feinberg AP . Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors . Science . 1985;227:642–645
  6. Abrahamson G , Fraser NJ , Boyd J , Craig I , Wainscoat JS . A highly informative X-chromosome probe, M27 beta, can be used for the determination of tumour clonality . Br J Haematol . 1990;74:371–372
  7. Allen AJ , Gale RE , Harrison CN , Machin SJ , Linch DC . Lack of pathogenic mutations in the 5′-untranslated region of the thrombopoietin gene in patients with non-familial essential thrombocythaemia . Eur J Haematol . 2001;67:232–237
  8. Curnutte JT , Hopkins PJ , Kuhl W , Beutler E . Studying X inactivation . Lancet . 1992;339:749
  9. Prchal JT , Guan YL , Prchal JF , Barany F . Transcriptional analysis of the active X-chromosome in normal and clonal hematopoiesis . Blood . 1993;81:269–271 (letter)
  10. Liu E , Jelinek J , Pastore YD , Guan Y , Prchal JF , Prchal JT . Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin . Blood . 2003;101:3294–3301
  11. Prchal JT . Polycythemia vera and other primary polycythemias . Curr Opin Hematol . 2005;12:112–116
  12. Kralovics R , Guan Y , Prchal JT . Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera . Exp Hematol . 2002;30:229–236
  13. Popat U, Frost A, Reddy V, Liu E, May R, Bag R, et al. Myelofibrosis (New onset in association with pulmonary arterial hypertension) . Ann Intern Med . 2005;143:466–467
  14. Mitterbauer G , Winkler K , Gisslinger H , Geissler K , Lechner K , Mannhalter C . Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis . Am J Clin Pathol . 1999;112:93–100
  15. El Kassar N , Hetet G , Briere J , Grandchamp B . Clonality analysis of hematopoiesis in essential thrombocythemia (Advantages of studying T lymphocytes and platelets) . Blood . 1997;89:128–134
  16. Harrison CN , Gale RE , Machin SJ , Linch DC . A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications . Blood . 1999;93:417–424
  17. Shih LY , Lin TL , Lai CL , Dunn P , Wu JH , Wang PN , et al.   Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia . Blood . 2002;100:1596–1601
  18. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera . Nature . 2005;434:1144–1148
  19. Baxter EJ , Scott LM , Campbell PJ , East C , Fourouclas N , Swanton S , et al.   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders . Lancet . 2005;365:1054–1061
  20. Levine RL , Wadleigh M , Cools J , Ebert BL , Wernig G , Huntly BJ , et al.   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis . Cancer Cell . 2005;7:387–397
  21. Kralovics R , Passamonti F , Buser AS , Teo SS , Tiedt R , Passweg JR , et al.   A gain-of-function mutation of JAK2 in myeloproliferative disorders . N Engl J Med . 2005;352:1779–1790
  22. Zhao R , Xing S , Li Z , Fu X , Li Q , Krantz SB , et al.   Identification of an acquired JAK2 mutation in Polycythemia vera . J Biol Chem . 2005;280:22788–22792
  23. Jones AV , Kreil S , Zoi K , Waghorn K , Curtis C , Zhang L , et al.   Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders . Blood . 2005; May 26 [Epub ahead of print]
  24. Steensma DP , Dewald GW , Lasho TL , Powell HL , McClure RF , Levine RL , et al.   The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and the myelodysplastic syndrome . Blood . 2005;106:1207–1209
  25. Goerttler PS , Kreutz C , Donauer J , Faller D , Maiwald T , Marz E , et al.   Gene expression profiling in polycythaemia vera (overexpression of transcription factor NF-E2) . Br J Haematol . 2005;129:138–150
  26. Jelinek J , Oki Y , Gharibyan V , Bueso-Ramos C , Prchal JT , Verstovsek S , et al.   JAK2 mutation 1849G→T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia . Blood . 2005; Jul 21 [Epub ahead of print]
  27. Levine RL , Loriaux M , Huntly BJP , Loh ML , Beran M , Stoffgren E , et al.   The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia . Blood . 2005; Aug 4 [Epub ahead of print]
  28. Kralovics R , Teo SS , Buser AS , Brutsche M , Tiedt R , Tichelli A , et al.   Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 . Blood . 2005; Aug 4 [Epub ahead of print]

PII: S0037-1963(05)00146-0

doi: 10.1053/j.seminhematol.2005.08.004

Seminars in Hematology
Volume 42, Issue 4 , Pages 181-183 , October 2005

Article Tools